EVOLUS, INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
EVOLUS, INC. (EOLS) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$251.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-05
- EVOLUS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$251.00K, a 204.58% decline year-over-year.
- EVOLUS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$122.00K, a 284.85% decline year-over-year.
- EVOLUS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $462.00K.
- EVOLUS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-06-30 was $240.00K.
- EVOLUS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $749.00K.
- EVOLUS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$478.00K.
- EVOLUS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was -$90.00K.
- EVOLUS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$337.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$251.00K 10-Q · filed 2026-08-05 | -$373.00K derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-31 | -$122.00K 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $749.00K 10-K · filed 2026-03-03 | |||
| 2025-09-30 | $462.00K 10-Q · filed 2025-11-05 | $702.00K derived: sum of 2 quarters · filed 2026-08-05 | $768.00K derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-06-30 | $240.00K 10-Q · filed 2026-08-05 | $306.00K derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $66.00K 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | -$478.00K 10-K · filed 2026-03-03 | |||
| 2024-09-30 | -$88.00K 10-Q · filed 2025-11-05 | -$132.00K derived: sum of 2 quarters · filed 2025-11-05 | -$262.00K derived: sum of 3 quarters · filed 2025-11-05 | |
| 2024-06-30 | -$44.00K 10-Q · filed 2025-11-05 | -$174.00K derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2024-03-31 | -$130.00K 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | -$90.00K 10-K · filed 2026-03-03 | |||
| 2023-09-30 | -$138.00K 10-Q · filed 2024-11-06 | -$190.00K derived: sum of 2 quarters · filed 2024-11-06 | -$269.00K derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | -$52.00K 10-Q · filed 2024-11-06 | -$131.00K derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | -$79.00K 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | -$337.00K 10-K · filed 2025-03-04 | |||
| 2022-09-30 | -$203.00K 10-Q · filed 2023-11-07 | -$265.00K derived: sum of 2 quarters · filed 2023-11-07 | -$368.00K derived: sum of 3 quarters · filed 2023-11-07 | |
| 2022-06-30 | -$62.00K 10-Q · filed 2023-11-07 | -$165.00K derived: sum of 2 quarters · filed 2023-11-07 | ||
| 2022-03-31 | -$103.00K 10-Q · filed 2023-11-07 | |||
| 2020-12-31 | -$6.00K 10-K · filed 2022-03-03 | |||
| 2020-09-30 | -$16.00K 10-Q · filed 2021-11-02 | -$222.00K derived: sum of 2 quarters · filed 2021-11-02 | -$3.00K derived: sum of 3 quarters · filed 2021-11-02 | |
| 2020-06-30 | -$206.00K 10-Q · filed 2021-11-02 | $13.00K derived: sum of 2 quarters · filed 2021-11-02 | ||
| 2020-03-31 | $219.00K 10-Q · filed 2021-11-02 | |||
| 2019-12-31 | $6.00K 10-K · filed 2021-03-25 | |||
| 2019-09-30 | -$24.00K 10-Q · filed 2020-10-29 | $28.00K derived: sum of 2 quarters · filed 2020-10-29 | $19.00K derived: sum of 3 quarters · filed 2020-10-29 | |
| 2019-06-30 | $52.00K 10-Q · filed 2020-10-29 | $43.00K derived: sum of 2 quarters · filed 2020-10-29 | ||
| 2019-03-31 | -$9.00K 10-Q · filed 2020-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |